Celyad (Group)

https://www.celyad.com

LinkedIn: https://www.linkedin.com/company/celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell autologous and allogeneic platforms have the potential to treat a broad range of solid and hematologic tumors. After having demonstrated safety, its lead oncology autologous CAR-T therapy CYAD-01 (CART NKG2D) is now currently being evaluated in several Phase I clinical trials to assess the clinical activity of multiple administrations of autologous CYAD-01 cells in solid cancer (metastatic colorectal cancer) and hematological tumors (acute myeloid leukemia) with or without being concurrently administered with standard-of-care treatments (preconditioning chemotherapy). Concomitantly, Celyad is developing CYAD-101, first-in-class, investigational, non-gene edited, allogeneic (donor derived) CAR-T therapy co-expressing the CAR-T NKG2D and the novel inhibitory peptide TIM (T cell receptor [TCR] Inhibiting Molecule). The expression of TIM reduces signaling of the TCR complex and could therefore reduce or eliminate Graft versus Host Disease (GvHD). CYAD-101 is evaluated in a Phase I trial for the treatment of patients with mCRC. Preliminary results are expected in second half of 2019. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD. *

	Start	2015-05-05 renamed
	Predecessor	Cardio3 BioSciences (C3BS) (Group)
	Industry	C-Cure® cell therapy
	Industry 2	C-Cathez®
	Person	Petti, Filippo (Celyad 201904 interim CEO 201809– CFO before Wells Fargo Securities + William Blair + Webush Securities)
	Person 2	Moore, Anne (Celyad 201904–201911 VP Corp Strategy before Bryan, Garnier Paris + Credit Suisse LEFT 11/19)

	Region	Mont-Saint-Guibert
	Country	Belgium
	Street	12 Rue Edouard Belin
	City	1435 Mont-Saint-Guibert
	Tel	+32-10-394100
		Address record changed: 2024-01-05

Basic data	Employees	C: 51 to 100 (2015-12-31)
	Currency	EUR
	Annual sales	3,115,000 (revenues, consolidated (2018) 2018-12-31)
	Profit	-37,427,000 (2018-12-31)
	Cash	40,542,000 (2018-12-31)

		* Document for »About Section«: Celyad S.A.. (3/28/19). "Press Release: Celyad Appoints Filippo Petti as Chief Executive Officer. Dr Christian Homsy Continues as Non-executive Director and Chair of the Strategy Committee of the Board of Directors". Mont-Saint-Guibert.

		Record changed: 2025-03-16